Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning
regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2
in patients with lymphoid malignancies.